Diagnosis of haematological disease using anti-i. I. Disorders with lymphocytosis.

Using cytotoxicity and antibody-binding tests, the i antigen was measured on the blood lymphocytes of normal subjects and of patients in whom a diagnosis of chronic lymphocytic leukemia (CLL) was considered because of a slight lymphocytosis in the blood and bone marrow. Among 25 patients, 15 had a normal amount of i antigen; in 10 there was a marked reduction in i antigen, such as is found in typical CLL. Similar studies were done on lymphocytes from 15 patients with clinical and morphological findings usually associated with lymphosarcoma cell leukemia (LSL).

Diagnosis of haematological disease using anti-i. II. Distinction between acute myeloblastic and acute lymphoblastic leukaemia.

Leukaemic blast cells were obtained from the blood of six patients with acute lymphoblastic leukaemia (ALL) and 15 patients with acute myeloblastic leukaemia (AML). The blasts were compared with lymphocytes from normal subjects in cytotoxicity and 125I-labelled antibody binding tests using several examples of anti-i. As much i antigen was detected on ALL blasts as on normal lymphocytes; much less i antigen was detected on AML blasts.

Chronic allogeneic disease. II. Development of lymphomas.

The incidence of lymphomas in 371 CAF(1) mice injected with BALB/c spleen cells was compared with that in 324 control CAF(1) mice. A high incidence of lymphomas was found in the treated mice, but not in the control animals. The development of the neoplasms was a function of the number of parental cells administered.

Chronic allogeneic disease. I. Development of glomerulonephritis.

Glomerulonephritis, often accompanied by the nephrotic syndrome, developed in CAF(1) mice following the administration of spleen cells from normal BALB/c mice. The renal lesion was membranous glomerulonephritis. When studied with fluorescein-conjugated antisera to either mouse gamma globulin or beta(1C)-globulin, the glomeruli contained beaded and irregular deposits of these immunoproteins.